Objective: To investigate the preventive effect of misoprostol against non-steroidal anti-inflammatory drug (NSAID)-induced intestinal injury in mice.
Methods: NSAID-induced intestinal injury model was established through diclofenac sodium. Sixty specific-pathogen-free (SPF) BABL/c male mice were randomly divided into the following five groups: normal, model and three misoprostol groups with different concentrations (200, 400, 800 μg/kg). Misoprostol was given to aforementioned three misoprostol groups by gavage once a day for 6 days. In the fourth day afternoon, 5 mg/kg (10 mL/kg) diclofenac was fed to all mice by gavage except for normal group. On the seventh day, all mice were sacrificed and intestinal permeability was detected using FITC labeled dextran. The intestinal tissues were taken for detecting the mRNA and protein expressions of intestinal glucose regulated protein 78 (GRP78), C/EBP homologous protein (CHOP) and tumor necrosis factor alpha (TNF-α) through HE staining, reverse transcription PCR and Western blotting, respectively.
Results: Compared with the normal group, intestinal mucosa in the model group was seriously damaged and intestinal permeability significantly increased. The intestinal mucosal villus degeneration, necrosis, shedding, and inflammatory cell infiltration occurred in the model group. Yet, intestinal mucosal injury in different misoprostol groups was less severe. Their intestinal mucosal permeability was improved. The expressions of GRP78 protein and TNF-α, CHOP mRNAs on intestine were significantly reduced compared with those of the model group.
Conclusion: Misoprostol has preventive effect against NSAID-induced intestinal diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In Vitro Protective Effects of a Standardized Extract of (L.) Mill. Cladodes and L. Leaves Against Indomethacin-Induced Intestinal Epithelial Cell Injury.
Antioxidants (Basel)
December 2024
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno D'Alcontres 31, 98166 Messina, Italy.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can induce serious adverse effects in gastrointestinal (GI) mucosa, increasing intestinal permeability and leading to mitochondrial dysfunction, oxidative stress, apoptosis and inflammation. As proton pump inhibitors are effective in protecting against NSAID-induced gastropathy but not NSAID-induced enteropathy, current research is focused on natural products as protective substances for therapy and prevention of intestinal injury. Herein, through the use of an in vitro model based on intestinal epithelial cell (Caco-2) damage caused by indomethacin (INDO), we examined the protective activity of a commercially available standardized extract (OFI+OE) from (L.
View Article and Find Full Text PDFNonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medications for the management of chronic pain; however, they are associated with numerous gastrointestinal (GI) adverse events. Although many mechanisms have been suggested, NSAID-induced enteropathy has been thought to be primarily due to inhibition of both cyclooxygenases (COX) -1 and -2, which results in suppression of prostaglandin synthesis. Yet surprisingly, we found that concomitant postnatal deletion of and over 10 months failed to cause intestinal injury in mice unless they were treated with naproxen or its structural analog, phenylpropionic acid, which is not a COX inhibitor.
View Article and Find Full Text PDFIntestinal webs are either congenital or acquired. There are few reported cases of either chemotherapy or nonsteroidal anti-inflammatory medications leading to acquired intestinal webs in adults. There are limited descriptions of endoscopic interventions used for therapy of numerous duodenal webs in pediatrics.
View Article and Find Full Text PDFEffect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy.
Sci Rep
November 2024
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
Article Synopsis
- The use of NSAIDs for chronic conditions has led to an increase in NSAID-induced enteropathy, creating a need for effective preventive and treatment strategies.
- Tegoprazan was tested on human epithelial cells exposed to indomethacin, showing a significant improvement in cell viability and restoration of tight-junction protein levels, which are crucial for intestinal health.
- The study concluded that tegoprazan protects small intestinal epithelial cells from NSAID-induced damage by enhancing tight junction protein expression and reducing inflammation and cell death.
A Study on the Glucose Breath Test Positivity Rate and Occurrence of Small Intestine Bacterial Overgrowth-Related Symptoms Caused by Long-Term Use of Proton Pump Inhibitor (PPI) Versus Potassium-Competitive Acid Blocker (P-CAB) in Elderly Patients: SIBO Between PPI and P-CAB.
Adv Pharmacol Pharm Sci
October 2024
Department of Internal Medicine, St. Vincent Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Long-term acid suppression with proton pump inhibitors (PPI) leads to hypochlorhydria and facilitates the growth of bacterial flora in the small intestine. Novel acid-suppressants called potassium-competitive acid blockers (P-CABs) seem to be superior to PPIs. However, data on the risk of small intestinal bacterial overgrowth (SIBO) in patients taking P-CABs are limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!